SLXN Silexion Therapeutics Corp
$0.15▼ -7.54%
Healthcare
Other
Volume 378.9K
Avg Volume (10D) 1.86M
Key Metrics & Fundamentals
Market Cap
$2.22M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.14 - 34.70
% vs 50 MA
-48.03%
% vs 200 MA
-97.78%
RSI-14
32.6
MACD Histogram
+0.0200
Beta (1Y vs SPY)
3.52
Free Cash Flow
-$2.93M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.64M
COGS
–
Operating Exp
$3.68M
Operating Income
-$3.68M
EBIT
-$3.68M
Pretax Income
-$3.55M
Net Income
-$3.55M
EPS (Diluted)
-5.17
Price & Volume History
Loading chart…
Recent News
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
GlobeNewswire · Sep 30, 2026 8:00 AM ET
Silexion Therapeutics Announces Exercise of Warrants
GlobeNewswire · Sep 29, 2026 8:03 AM ET
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
GlobeNewswire · Sep 28, 2026 8:30 AM ET
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
GlobeNewswire · Sep 9, 2026 9:00 AM ET
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 14, 2026 8:45 AM ET
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
GlobeNewswire · Aug 11, 2026 8:01 PM ET
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
GlobeNewswire · Aug 4, 2026 9:15 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SLXN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.